

Tablica 11.1. Prvih 30 lijekova po financijskoj potrošnji izraženo u eurima, na teret HZZO-a u 2024. godini

RBR	ATK	INN	UKUPNI IZNOS EUR
1	L01FF02	pembrolizumab	94.975.708
2	L02BB04	enzalutamid	24.407.074
3	V06DX03	namirnice za enteralnu primjenu	23.346.526
4	L01EL01	ibrutinib	20.622.250
5	L01FF01	nivolumab	20.539.652
6	L01FG01	bevacizumab	20.084.303
7	B01AF01	rivaroksaban	19.410.233
8	L01FC01	daratumumab	19.023.586
9	L01FF05	atezolizumab	18.582.657
10	L04AA36	okrelizumab	18.026.758
11	J06BA02	imunoglobulini, humani, za i.v. primjenu	17.148.291
12	A10BJ06	semaglutid	15.549.059
13	L01FD02	pertuzumab	14.969.478
14	A02BC02	pantoprazol	14.017.761
15	L04AX04	lenalidomid	13.106.947
16	R07AX32	ivakaftor, tezakaftor i eleksakaftor	13.038.349
17	B01AF02	apiksaban	12.554.680
18	L01XX52	venetoklaks	12.385.750
19	L04AB02	infliksimab	12.169.658
20	L01FY01	pertuzumab i trastuzumab	12.116.015
21	C09DX04	valsartan i sakubitril	11.821.046
22	L04AB04	adalimumab	11.486.408
23	N05AX13	paliperidon	11.132.633
24	C10AA05	atorvastatin	10.895.539
25	M09AX10	risdiplam	10.791.297
26	L01EF03	abemaciclib	10.760.112
27	C09BX01	perindopril, amlodipin i indapamid	10.537.633
28	B05AA01	albumin, ljudski	10.478.844
29	B05BB01	elektroliti	10.355.183
30	L03AA13	pegfilgrastim	9.957.073